MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis.
Eleonora TavazziRobert ZivadinovMichael G DwyerDejan JakimovskiTarun SinghalBianca Weinstock-GuttmanNiels P BergslandPublished in: Expert review of neurotherapeutics (2020)
Imaging biomarkers capable of detecting tissue damage early on in the disease, with the potential to be applied in multicenter trials and at an individual level in clinical settings, are strongly needed. Several measures have been proposed, which exploit advanced imaging acquisitions and/or incorporate sophisticated post-processing, can quantify irreversible tissue damage. The progressively wider use of high-strength field MRI and the development of more advanced imaging techniques will help capture the missing pieces of the MS puzzle. The ability to more reliably identify those at risk for disability progression will allow for earlier intervention with the aim to favorably alter the disease course.